Literature DB >> 16192114

Revisiting "freely given informed consent" in relation to the developing world: role of an ombudsman.

Athula Sumathipala1, Sisira Siribaddana.   

Abstract

BACKGROUND: Establishment of Sri Lankan Twin Registry demanded development of ethical guidelines, as an effective ethical framework was not available in Sri Lanka.
DESIGN: Objectives were to find out whether the ombudsman concept exists in current informed consent practices and to investigate opinion about ombudsmen. We searched Pub Med, conducted a postal survey, and monitored Internet discussion.
RESULTS: The responses were categorized into current practices and existing models in informed consent process, reservations expressed about current practices, arguments supporting the concept, concerns and issues, alternatives, and how to implement the proposal. The concept of a third person is not entirely novel. How to find a truly independent person, the financial implication, confidentiality, obligations, and liabilities of ombudsmen, also emerged.
CONCLUSIONS: The concept of an ombudsman is conceptually and ethically sound and acceptable but the challenges posed by this very same solution to creating a better process of informed consent will have to be faced.

Entities:  

Keywords:  Biomedical and Behavioral Research; Empirical Approach

Mesh:

Year:  2004        PMID: 16192114     DOI: 10.1080/15265160490505498

Source DB:  PubMed          Journal:  Am J Bioeth        ISSN: 1526-5161            Impact factor:   11.229


  2 in total

1.  Issues concerning informed consent for medical research among non-westernized ethnic minority patients in the UK.

Authors:  Simon Dein; Kamaldeep Bhui
Journal:  J R Soc Med       Date:  2005-08       Impact factor: 18.000

2.  Informed consent in Sri Lanka: a survey among ethics committee members.

Authors:  Athula Sumathipala; Sisira Siribaddana; Suwin Hewage; Manura Lekamwattage; Manjula Athukorale; Chesmal Siriwardhana; Joanna Murray; Martin Prince
Journal:  BMC Med Ethics       Date:  2008-05-20       Impact factor: 2.652

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.